Preclinical study on Cynata’s (ASX: CYP) Cymerus™ MSCs for heart disease receives funding

Image Source: © Dizain777 | Megapixl.com


  • St Vincent's Institute of Medical Research, Melbourne has received a grant of AU$1 million to investigate Cynata’s mesenchymal stem cells (MSCs) in ischaemic heart disease (IHD).
  • The study is targeted at expediting the development of a new, safe, and minimally invasive method to deliver the beneficial effects of Cymerus MSCs.
  • IHD is a major cause of death globally, and in Australia, it accounts for nearly 12% of all deaths.

Cynata Therapeutics (ASX:CYP), an ASX-listed company focused on developing a proprietary stem cell platform technology, has provided an important update regarding a grant for a pre-clinical study.

The Australian Government National Health and Medical Research Council (NHMRC) has conferred a grant of about AU$1 million to fund an important preclinical research project on Cynata's Cymerus™ mesenchymal stem cells (MSCs) as a potential treatment for ischaemic heart disease (IHD).

The grant has been provided to St Vincent's Institute of Medical Research, Melbourne (SVIMR) under the NHMRC 2021 MRFF Cardiovascular Health Mission. The project will be headed by Dr Shiang (Max) Lim, Head of Cardiac Regeneration Laboratory, SVIMR and is expected to run for a period of two years.

Cymerus MSCs for the study will be supplied by Cynata at its own cost. Under the investigation, Cymerus MSCs will be encapsulated in a clinical-grade device implanted below the skin (subcutaneously). It is targeted to enable sustained delivery of the bioactive molecules released by the MSCs.



The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and